Bio Affinity Technologies, Inc. BIAF
Institutional shares held
239,689
0
calls
0
puts
Total value of holdings
$639K
$0
calls
$0
puts
Market Cap
$7.28M
2,727,580
Shares Out.
Institutional ownership
8.79%
# of Institutions
15
We take great care to ensure that the data presented and summarized in this overview for bioAffinity Technologies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BIAF
View all-
Vanguard Group Inc Valley Forge, PA70.3KShares$187,7700.0% of portfolio
-
Geode Capital Management, LLC Boston, MA42.1KShares$112,3480.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny37.5KShares$100,1250.0% of portfolio
-
Captrust Financial Advisors Raleigh, NC27.9KShares$74,4520.0% of portfolio
-
State Street Corp Boston, MA17.6KShares$46,9920.0% of portfolio
-
Northern Trust Corp Chicago, IL13.7KShares$36,4770.0% of portfolio
-
Creative Planning Overland Park, KS12.1KShares$32,2930.0% of portfolio
-
Sheaff Brock Investment Advisors, LLC10KShares$26,7000.0% of portfolio
-
Ifp Advisors, Inc5KShares$13,3500.0% of portfolio
-
Tower Research Capital LLC (Trc) New York, NY3.35KShares$8,9360.0% of portfolio
Latest Institutional Activity in BIAF
Top Purchases
Top Sells
About BIAF
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Insider Transactions at BIAF
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 12
2024
|
Gary D Rubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,296
+6.85%
|
-
|
|
Jun 12
2024
|
Robert A. Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,296
+5.99%
|
-
|
|
Jun 12
2024
|
Peter S Knight Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,296
+9.02%
|
-
|
|
Jun 12
2024
|
Jamie Platt Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,296
+28.35%
|
-
|
|
Jun 12
2024
|
Roby Joyce Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,296
+20.17%
|
-
|
|
Jun 12
2024
|
Maria Zannes President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,296
+3.81%
|
-
|
|
Jun 12
2024
|
Steven Girgenti Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
8,296
+0.8%
|
-
|
|
Jun 12
2024
|
Stuart Diamond Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,296
+11.27%
|
-
|
|
Apr 08
2024
|
Maria Zannes President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
28,264
-12.32%
|
$56,528
$2.65 P/Share
|
|
Apr 08
2024
|
Maria Zannes President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
64,848
+22.03%
|
$64,848
$1.16 P/Share
|
|
Apr 04
2024
|
Timothy P Zannes Secretary, EVP, Gen. Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
29,031
-38.63%
|
$58,062
$2.58 P/Share
|
|
Apr 04
2024
|
Timothy P Zannes Secretary, EVP, Gen. Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
64,848
+46.32%
|
$64,848
$1.16 P/Share
|
|
Apr 03
2024
|
Steven Girgenti Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
33,438
-3.16%
|
$66,876
$2.24 P/Share
|
|
Apr 03
2024
|
Steven Girgenti Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
64,848
+5.78%
|
$64,848
$1.16 P/Share
|
|
Feb 26
2024
|
Robert A. Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
64,848
+34.73%
|
$64,848
$1.16 P/Share
|
|
Feb 16
2024
|
Steven Girgenti Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
39,474
+3.83%
|
$39,474
$1.52 P/Share
|
|
Jan 31
2024
|
Timothy P Zannes Secretary, EVP, Gen. Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
6,688
+39.35%
|
-
|
|
Jan 31
2024
|
Steven Girgenti Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
11,943
+1.24%
|
-
|
|
Jan 31
2024
|
Vivienne I Rebel Chief Sci. & Med. Officer, EVP |
BUY
Grant, award, or other acquisition
|
Direct |
31,847
+40.79%
|
-
|
|
Jan 31
2024
|
Xavier Trinidad Reveles Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,720
+45.12%
|
-
|
Last 12 Months Summary
Buy / Acquisition
793K
Shares
From
17
Insiders
| Grant, award, or other acquisition | 533K shares |
|---|---|
| Exercise of conversion of derivative security | 259K shares |
Sell / Disposition
90.7K
Shares
From
3
Insiders
| Payment of exercise price or tax liability | 90.7K shares |
|---|